Heart failure (HF) prevalence is rising due to population aging and increasing risk factor incidence, thereby posing a significant global public health challenge. Disease management programs (DMPs) play a crucial role in managing HF and optimizing postevent health outcomes. Through a systematic review and meta-analysis, this study aimed to evaluate the effectiveness of DMPs following an HF event. Five electronic databases-Embase, PubMed, Web of Science, Scopus, and CINAHL-were searched for relevant studies published before December 2023. Studies with randomized controlled trials evaluating DMPs versus placebo for patients after an HF event were selected. Twelve articles were included in the meta-analysis, with a total of 3844 patients. The intervention group showed clinically significant improvement in exercise capacity [mean difference (95% confidence interval), 53.33 (43.40-67.26); P < 0.00001]; physical activity [-5.76 (-8.86 to -2.66); P = 0.0003]; emotional well-being [-2.32 (-4.39 to -0.25); P = 0.03]; and quality of life [-9.13 (-16.79 to -1.48); P = 0.02) compared with the control group. Furthermore, the control group showed significantly higher hospital admissions (P = 0.0002); readmissions (P = 0.00001); and mortality due to HF causes (P = 0.003) than the intervention group. DMPs have a positive effect on patients who have experienced an HF event by improving exercise capacity, physical activity, emotional well-being, and quality of life and reducing hospital admissions, readmissions, and mortality due to HF causes.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.